Intarcia Raises $50 Million

Intarcia Therapeutics Inc., an Emeryville, Calif.-based drug company with lead candidates focused on hepatitis C and Type 2 diabetes, has raised $50 million in Series BB funding. New Leaf Venture Partners led the deal, and was joined by Quilvest Ventures and return backers New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund and Granite Global Ventures. The company has now raised around $194 million in total VC funding since its 1997 inception, including $50 million Series E round in 2004 at a post-money valuation of around $133 million.